

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect, or any other forms of damages arising from this translation.

March 30, 2026

To whom it may concern:

NIHON TRIM CO., LTD.
Representative: Shinkatsu Morisawa,
Chairman and CEO
(Securities code: 6788, Prime Market of
the Tokyo Stock Exchange)
Inquiries: Yasuhiro Daikoku,
Senior Managing Executive Officer and
General Manager of Administration
Division
(Tel: +81-(0) 6-6456-4600)

Notice Regarding Nomination of Candidate for Director

NIHON TRIM CO., LTD. (the “Company”) hereby announces that it has nominated a candidate for Director at the Board of Directors meeting held on March 28, 2026, as set forth below. This appointment will be formally determined subject to approval at the Annual General Meeting of Shareholders scheduled for late June 2026.

1. The name and career summary of the candidate for Director

Position	Name (Date of Birth)	Career summary	
Director (Part-time)	Takafumi Shimizu (March 17, 1973)	September 1998	Joined the Company
		August 2006	Vice President, PT. SUPER WAHANA TEHNO (Indonesia)
		April 2010	General Manager of Business Strategy & Management Department, the Company
		April 2013	Executive Officer responsible for overseas business and corporate planning, the Company
		September 2013	Resigned from the Company
		September 2013	Director, StemCell Institute Inc.
		June 2016	Representative Director and President, StemCell Institute Inc. (current position)

2. Reason for nomination

Mr. Takafumi Shimizu has practical experience at the Business Strategy & Management Department of the Company and possesses high-level expertise in the medical field and overseas business in particular. He also has management experience at StemCell Institute Inc.

In addition, he has a deep understanding of business management and management strategies of the Company and the Group, enabling him to make management decisions from a comprehensive perspective of the entire business. The Company expects him to contribute to highly transparent decision-making and strengthening of its governance system and has therefore nominated him as a candidate for Director of the Company.

* StemCell Institute Inc. is the Company’s consolidated subsidiary listed on TSE Growth Market (Securities Code: 7096). The Company currently holds 71.2% of its voting rights.

3. Scheduled date of appointment: Late June 2026